| INTRODUCTION
Biological medicines have revolutionised the management of immune-mediated inflammatory diseases (IMIDs). As the first patent protections for biologicals began to expire, the market has been opened to copy versions of the originator. A biosimilar is a product highly similar to an already authorised biological, with no clinical meaningful difference in efficacy, safety, and immunogenicity, compared with the originator. 1 Since 2013, accumulating clinical data showed that the use of biosimilars, and the switch from an originator biological to a biosimilar, are acceptable and safe in patients with different IMIDs. [2] [3] [4] [5] [6] [7] [8] Current society guidelines in dermatology, rheumatology and IBD reflect this.
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The nocebo effect is defined as a negative effect of a pharmacological or nonpharmacological medical treatment that is induced by patients' expectations, and that is unrelated to the physiological action of the treatment. 12 It has been recognised as an important clinical challenge in the current era of biosimilars, since it can lower patients' quality of life and negatively affect treatment adherence rates. 13 Evidence that the nocebo effect might indeed lead to unnecessary cessation of biologic treatment is mainly indirectly derived from open-label observational studies, because doubleblinded trials are less susceptible to the nocebo effect. [14] [15] [16] [17] In the BIO-SWITCH study, 192 patients with rheumatoid arthritis (RA), psoriatic arthritis or ankylosing spondylitis (AS) were observed after transition from infliximab originator to infliximab biosimilar CT-P13. 14 With a median follow-up of six months, one quarter of patients discontinued treatment with CT-P13. This high drop-out rate was mainly due to subjective disease features and adverse events, suggesting that incorrect attribution and/or the nocebo effect were the main drivers. 14 Other open-label observational studies confirmed that treatment persistence after switching to a biosimilar was negatively influenced by mainly subjective health complaints and patient-reported outcomes, also hinting towards a role of the nocebo effect. [15] [16] [17] Initiating a biosimilar should be undertaken after a shared decision-making process including physicians, nurses, pharmacists, and patients. 11 But the majority of patients is not familiar with biosimilars, and three quarters of those who are, have concerns about them. 18 Furthermore, "forced switching" is a reality that some countries and organisations face, 19 which might lead to an increased risk of the nocebo effect.
Although an increasing number of IBD patients are now treated with biosimilars, and the awareness of the nocebo effect is gradually rising, practical recommendations to guide health-care providers about the nocebo effect were still lacking. Therefore, a
European consensus group aimed to review the literature and develop clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. Additional, general statements and future research perspectives were formulated.
| MATERIALS AND METHODS

| Consensus group
The consensus group on the nocebo effect in biosimilar-treated IBD patients ("NOCE-BIO Consensus Group") was composed of 19 members and included gastroenterologists with expertise in IBD (7), pharmacists (3), oncologists (2), rheumatologists (2), methodologists (2) and one dermatologist, one psychologist and one nurse specialist in IBD. The aim was to involve all health-care providers involved in IBD management and to be representative of at least five European countries (Belgium, Portugal, Italy, France, United Kingdom); for feasibility reasons, mainly health-care providers working in centers of the lead authors (SD and LPB) were selected. A list of the members of the consensus group, including their full affiliations and roles during the consensus process, is provided in Data S1.
| Scope and purpose
On review of the literature on the nocebo effect, the consensus group aimed to find specific information about its prevention and management in biosimilar-treated IBD patients. The consensus development process was initiated in April 2018 by the preparation of the consensus group meeting that took place in July 2018. The final manuscript was submitted for publication in December 2018. and Cochrane CENTRAL from database inception up to July 2018.
| Sources and searches
Detailed search strategy and results of this literature review were published previously. 13 Randomised controlled trials specifically examining the nocebo effect in biosimilar-treated IBD patients were lacking. At the time of the consensus meeting, there was only one interventional study examining the nocebo response rate in biosimilar-treated patients with IBD. 20 Another study, however only available in abstract format, examined an enhanced communication strategy to prevent the nocebo effect in IMID-patients switching from a biologic originator to a biosimilar, but no IBD patients were included. 21 Nevertheless, this publication was also taken into account when drafting and voting the consensus statements, since the members of the consensus group felt that its findings could be extrapolated to IBD patients. Other, indirect, evidence about the impact of the nocebo effect in biosimilar-treated patients was extracted from open-label observational switching studies. Again, the majority of this indirect evidence was extrapolated from studies conducted in patients with rheumatic diseases, 6, 14, 15 however two studies also included IBD patients. 16, 17 There were no data about the etiology and risk factors of the nocebo effect in biosimilar-treated IBD patients, however one systematic review summarised contributing factors to the nocebo effect across other indications. 
| Consensus meeting and voting process
All members of the consensus group were invited to a one-day consensus meeting, which was held in Milan, Italy in July 2018. Thirteen out of 19 members attended the meeting and participated in the voting process. Background data and supporting evidence from the literature review were first presented by three members of the consensus group (LP, SD and LPB), and were also sent by e-mail to those members of the consensus group that could not attend the meeting. Preliminary consensus statements (drafted by LP, SD and LPB) were then revealed. The phrasing of these preliminary statements was discussed and finalised.
Two preliminary statements, handling about the definition and the consequences of the nocebo effect, were eliminated before the actual voting took place. Participants unanimously decided to discuss these topics in the final version of the article, rather than to keep them as separate statements. Three additional statements were constructed during the meeting following group discussion. Eventually, participants voted on their level of agreement with each specific statement. A statement was accepted if >75% of participants voted 4 ("agree") or 5 ("strongly agree") on a scale of 1 to 5 (with 1, 2 and 3 indicating "disagree strongly", "disagree", and "uncertain" respectively). If consensus was not reached, statements were revised after an additional debate, and a new voting round took place. Evidence for each statement was graded in regard to its quality (high, moderate, low, very low) as described in GRADE. 23, 24 All members of the consensus group participated in the revision of the manuscript and agreed with the final version of it. The nocebo effect occurred in 12.8% of patients in a study that converted patients with different IMIDs from infliximab originator to infliximab biosimilar, and monitored the nocebo effect rate after a switch back to the originator. 20 Similar rates were observed in biosimilar-treated patients with IBD and biosimilar-treated patients with a rheumatologic condition (12.9% vs 12.5% respectively). 
| Role of the funding sources
| Risk factors
Data about the risk factors for the nocebo effect in the specific subgroup of biosimilar-treated IBD patients are lacking. One systematic review identified experimentally induced and baseline risk factors that contribute to the nocebo effect across other indications, with most data deducted from research on pain perception. 22 Five different strong predictors of the nocebo effect were defined as follows:
"learning by social observations", "perceived dose", "verbal suggestions of arousal and symptoms", "type of clinical condition" and "baseline symptom expectations". Four factors also enhance the risk of experiencing a nocebo effect, but mainly when interacting with others: "learning by classical conditioning", "likelihood suggestion", "self-awareness" and "negative affect". Furthermore, there was some evidence for the role of "personality" in the nocebo effect, but which facets of personality are involved in a nocebo response could not be specified. French study examining the outcome after switching from a biologic originator to a biosimilar, included 260 participants, of which 64 had IBD. 16 Only changes in patient-reported outcomes, and not in drug levels or objective biological parameters, were observed. 16 An observational, Dutch study followed 133 IBD patients that switched from a biologic originator to a biosimilar during a 12-month period. 17 One quarter of patients discontinued therapy, mainly due to subjective higher disease activity or adverse events. 17 Other, similarly designed studies only included patients with rheumatic diseases and not with IBD, but also suggested that subjective parameters are the main reason of treatment discontinuation after switching to a biosimilar.
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| Prevention and management
Interventional data in biosimilar-treated IBD patients do not exist.
One Dutch study recently investigated the impact of different communication strategies on the acceptance and persistence rates after switching from a biologic originator to a biosimilar in two groups of rheumatic patients. 21 Only one group was exposed to an enhanced communication strategy, including treatment by health-care providers that followed a 'soft skills' training about how to assuage patients' concerns regarding a biosimilar, and how to act if a patient had objective or subjective health complaints. Acceptance rates from switching to a biosimilar treatment were higher in participants exposed to this enhanced communication strategy, while treatment cessation of the biosimilar was more frequently seen, and more 
| DISCUSSION
The true burden of the nocebo effect in biosimilar-treated IBD patients is hard to estimate. In the only study that directly examined the prevalence of the nocebo effect in IBD patients switching from a biologic originator to a biosimilar, rates were higher than 10%. 20 This was similar compared with patients with rheumatic diseases, and shows that the nocebo effect is still under-recognised. As implied by its definition, the nocebo effect can occur not only when patients switch from a biologic originator to a biosimilar, but also when immediately initiating a biosimilar. The consensus group stated that caution is needed not to attribute every side effect experienced by a biosimilar-treated IBD patient directly to the treatment, because some side effects may be related to nocebo. Awareness is required especially in the interpretation of subjective health complaints by the patient. Indeed, open-label observational studies examining outcomes after switching from a biologic originator to a biosimilar showed no difference in objective disease markers such as infliximab drug levels, C-reactive protein levels and fecal calprotectin levels, [25] [26] [27] but could mark some differences regarding subjective disease features. 6, [14] [15] [16] [17] Although data about the nocebo effect and its impact in biosimilar-treated IBD patients remain scarce, research in many other fields, such as depression, 28 neuropathic pain perception, 29 and primary headache, 30 supports the influence of negative expectations on the occurrence of adverse symptoms, and consequently on patients'
well-being and adherence. However only supported by indirect evidence, 16 ,17 the nocebo effect can also lead to unnecessary cessation of biologic treatment, thereby altering IBD patients' outcomes in clinical practice and in clinical trials. 13 The consensus group expressed concerns that the nocebo effect may also negatively impact on the cost-savings of biosimilars, while the main objective of implementing biosimilars in IBD is economically driven. 31 Future Directions Statement 11. Due to the limited evidence of the nocebo effect in the biosimilars era, further research is needed (a) To better estimate the magnitude of the nocebo effect; (b) To identify risk factors associated with the nocebo effect; (c) To measure the impact of the nocebo effect on disease outcomes as well as the health-care system; (d) To design interventional studies to reduce and to prevent the nocebo effect.
(100% acceptance rate, very low-quality evidence)
providers is of crucial importance, as it will influence patients' expectations formed during the informed consent process. 32, 33 Expectations are also shaped through observations of other patients experiencing symptoms. 33 Additionally, the media influences patients' concerns about medical treatments. 34 For example, a recent study showed that news coverage in the previous month, and Google search volumes in the same month, were significant predictors of adverse event reporting in response to Gardasil vaccination in New
Zealand. 35 Similar effects can be expected regarding biosimilars in IBD.
The health-care provider plays an important role in the prevention and management of the nocebo effect in biosimilar-treated IBD patients. He should be aware of the nocebo effect and adopt strategies to minimise it. A recent survey among patients with different
IMIDs showed that patients accept a biosimilar more if it is prescribed and explained by their treating physician, compared with a strategy where a biosimilar is dispensed after changing the initial prescription without the consent of the physician. 18 The consensus group recognised unanimously the patient-health-care provider relationship as being the key driver of acceptance of biosimilars, limiting the risk of negative bias and the nocebo effect. This health-care provider community includes nurses, pharmacists, and psychologists, as well as treating physicians.
The effectiveness and safety of biosimilars in IBD is well-proven, 36, 37 but there remains a lack of knowledge about these data among patients, and this contributes to the nocebo effect. 18, 38 To minimise misconceptions, health-care providers should adequately inform and educate their patients. 39 Important steps are still needed to improve knowledge in health-care providers too, as five major gaps were revealed by a recent survey across more than one thousand US physicians that regularly use biologicals. 40 The awareness of health-care providers of the available data about biosimilars, and their ability to explain this information effectively to patients, will result in increased patient confidence in their treatment choice. 41 Patient education should not only include sharing of factual information about biosimilars, but also explicitly discussing the possibility of the nocebo effect. Indeed, more than three quarters of patients are unaware or do not believe in the nocebo effect, 42 while pointing out that the anticipation of fear of an adverse reaction can become a self-fulfilling prophecy may in itself help to obviate non-specific side effects.
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Education about biosimilars should be tailored to individual patients. A contextualised informed consent takes into account the severity of the disease, the possible side effects and the person being treated. 43, 44 It should provide the most transparency with the least potential harm, applying the principles of positive framing. This involves drawing attention to benefits rather than drawbacks, without refraining from delivering the necessary information. 45 Positive framing has shown to improve subjective patients' experiences following medical therapy. 46 When initiating a treatment, it is recommended to encourage patients to contact their health-care provider in case of 'any new or unusual symptoms', rather than labelling all potential non-specific side effects, especially in patients with a high risk of the nocebo effect. 43, 44 Despite the existence of clinical tools designed to enable the standardised assessment of patients' expectations to a medical treatment, 47, 48 
